At a glance
- Originator Merck & Co
- Class Analgesics
- Mechanism of Action Neurokinin 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Nausea and vomiting; Pain
Most Recent Events
- 08 Feb 2000 No-Development-Reported for Emesis in United Kingdom (Unknown route)
- 08 Feb 2000 No-Development-Reported for Emesis in USA (Unknown route)
- 08 Feb 2000 No-Development-Reported for Pain in USA (PO)